United States · FDA National Drug Code directory
EBGLYSS
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0002-7772_361eb12f-8b25-4174-a653-5b857e6abd03
- Product NDC
- 0002-7772
- Form
- INJECTION, SOLUTION
- Composition / generic term
- lebrikizumab-lbkz
- Labeler
- Eli Lilly and Company
- Marketing category
- BLA
- Marketing start / end (source format)
- 20240913
- Source listing expiry
- 20271231
Source-listed ingredients
- LEBRIKIZUMAB — 250 mg/2mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 SYRINGE in 1 CARTON (0002-7772-11) / 2 mL in 1 SYRINGE (0002-7772-01) · 0002-7772-11
- 2 SYRINGE in 1 CARTON (0002-7772-62) / 2 mL in 1 SYRINGE · 0002-7772-62
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →